IQVIA is trading higher today, tracking a broader upward trend across the medical diagnostics and research sector where peers like Medpace, Agilent, and Charles River Laboratories are also posting gains. This positive momentum follows the company's recent product announcements at TechIQ 2026, where it introduced IQVIA Life Science Models and IQVIA Explorer to enhance clinical trial and commercial decision-making for life sciences clients. Additionally, the stock is benefiting from favorable analyst sentiment, including a recent upward revision to earnings estimates and a Momentum Style Score of B, which highlights the company's steady performance leading into the next earnings report on October 27.